Звоните: +7 (812) 293-293-0

Dioscorea deltoidea properties

Dioscorea deltoidea is most common in India where it occupies extensive areas. Annually India supplies 60 - 100 tonns of Dioscorea, mainly of this type, used for diosgenin production. Diosgenin serves as a precursor for the industrial production of synthetic hormones and contraceptives. Dioscorea deltoidea and, in fact, diosgenin are the most studied substances. When entering woman’s body with food they help to normalize her hormonal status, regulate the menstrual cycle and prevent pain, maintain the tone of the female organs. 

Preparations of Dioscorea deltoidea are usually well tolerated, the side effects are extremely rare and are associated with individual intolerance to certain ingredients. Side effects of Dioscorea deltoidea products are associated with the presence of spirostanol glycosides. Furostanol glycosides, in contrast, do not have side effects. A unique feature of our Dioscorea deltoide biomass is the almost complete absence of spirostanol glycosides. Biomass has a high content of safe and having important pharmacological properties furostanol glycosides.

Steroidal glycosides that Dioscorea deltoidea contains are highly active compounds that is connected, presumably, with the combination in one molecule of two parts - steroid and carbohydrate ones. One of the important properties of these compounds that determines their biological activity is their ability to form complexes with the sterols. Thus steroidal glycosides possess hemolytic, hypocholesterolemic, antitumor, fungicide, antimicrobial and other biological activities [Tschesche R. 1973].

Dioscorea deltoidea preparations are used in the treatment and prevention of the following conditions:

  • diseases of the cardiovascular system
  • diseases of the central nervous system
  • dysfunctional changes in the female reproductive system
  • diseases of bones and joints
  • metabolic disorders
  • skin diseases
  • oncology
  • immunodeficiencies and autoimmune diseases

© BioPharmos Group 2011-2014

© BioPharmos Group 2011–2014